PLEASANTON, Calif., Oct. 11 /PRNewswire/ -- TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments ('EDBI') with strong support from current investors, Three Arch Partners and Adams Street Partners. "We are delighted to have Bio*One join our group of sophisticated blue chip investors who share our vision of developing innovative catheter and stent technology for coronary and peripheral interventional procedures," said Eitan Konstantino, Ph.D., President and CEO of TriReme Medical, Inc. "This investment will allow us to ramp up our commercial activities worldwide, continue to develop internal R&D programs and pursue key regulatory approvals for our products in large markets such as the US, Japan, and China."
Ms Chu Swee-Yeok, CEO EDBI and Bio*One Capital said, "We are impressed with the global vision of TriReme's management team and its ability to rapidly develop and gain regulatory approvals for its novel catheter technologies. Its strategy of positioning itself in Singapore will allow the company to tap on the fast growing Asian markets and enhance its competitiveness and reach." Mark Wan, General Partner at Three Arch Partners added, "This investment will allow TriReme to maximize the value of its R&D portfolio by providing for expansion of regulatory approvals and the creation of a commercial infrastructure that will drive revenue growth in the coming years."
About TriReme Medical, Inc.
Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The Company's novel ballo